Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines - PubMed (original) (raw)
Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines
Z Estrov et al. J Exp Med. 1993.
Abstract
Because human lymphotoxin (LT) was originally isolated from a lymphoblastoid cell line, we investigated the role of this molecule in three newly established Epstein-Barr virus (EBV)-infected human B cell lines. These lines were derived from acute lymphoblastic leukemia (Z-6), myelodysplastic syndrome (Z-43), and acute myelogenous leukemia (Z-55) patients who had a prior EBV infection. Each lymphoblastoid cell line had a karyotype that was different from that of the original parent leukemic cells, and all expressed B cell, but not T cell or myeloid surface markers. In all three lines, rearranged immunoglobulin heavy chain joining region (JH) bands were found, and the presence of EBV DNA was confirmed by Southern blotting. Z-6, Z-43, and Z-55 cell lines constitutively produced 192, 48, and 78 U/ml LT, respectively, as assessed by a cytotoxicity assay and antibody neutralization. Levels of tumor necrosis factor (TNF) were undetectable. Scatchard analysis revealed that all the cell lines expressed high-affinity TNF/LT receptors with receptor densities of 4197, 1258, and 1209 sites/cell on Z-6, Z-43, and Z-55, respectively. Furthermore, labeled TNF binding could be reversed by both unlabeled TNF, as well as by LT. Studies with p60 and p80 receptor-specific antibodies revealed that the three lines expressed primarily the p80 form of the TNF receptor. When studied in a clonogenic assay, exogenous LT stimulated proliferation of all three cell lines in a dose-dependent fashion at concentrations ranging from 25 to 500 U/ml. Similar results were obtained with [3H]TdR incorporation. Monoclonal anti-LT neutralizing antibodies at concentrations of 25-500 U/ml inhibited cellular multiplication in a dose-dependent manner. It is interesting that in spite of a common receptor, TNF (1,000 U/ml) had no direct effect on Z-55 cell growth, whereas it partially reversed the stimulatory effect of exogenous LT. In addition, TNF inhibited Z-6 and Z-43 cell proliferation, and its suppressive effect was reversed by exogenous LT. Both p80 and p60 forms of soluble TNF receptors suppressed the lymphoblastoid cell line proliferation and their inhibitory effect was partially reversed by LT. Our data suggest that (a) LT is an autocrine growth factor for EBV-transformed lymphoblastoid B cell lines; and (b) anti-LT antibodies, soluble TNF/LT receptors, and TNF itself can suppress the growth of lymphoblastoid cells, probably by modulating or competing with LT.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
- Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines.
Gibbons DL, Rowe M, Cope AP, Feldmann M, Brennan FM. Gibbons DL, et al. Eur J Immunol. 1994 Aug;24(8):1879-85. doi: 10.1002/eji.1830240825. Eur J Immunol. 1994. PMID: 8056047 - Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).
Estrov Z, Talpaz M, Zipf TF, Kantarjian HM, Ku S, Ouspenskaia MV, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R. Estrov Z, et al. J Cell Physiol. 1996 Mar;166(3):618-30. doi: 10.1002/(SICI)1097-4652(199603)166:3<618::AID-JCP17>3.0.CO;2-2. J Cell Physiol. 1996. PMID: 8600166 - Tumor necrosis factor and lymphotoxin. Qualitative and quantitative differences in the mediation of early and late cellular response.
Chaturvedi MM, LaPushin R, Aggarwal BB. Chaturvedi MM, et al. J Biol Chem. 1994 May 20;269(20):14575-83. J Biol Chem. 1994. PMID: 8182064 - Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.
Warzocha K, Bienvenu J, Coiffier B, Salles G. Warzocha K, et al. Eur Cytokine Netw. 1995 Mar-Apr;6(2):83-96. Eur Cytokine Netw. 1995. PMID: 7578992 Review. - Autocrine growth of human B lymphocytes: maintained response to autostimulatory factors is the special feature of immortalization by Epstein-Barr virus--a hypothesis.
Gordon J, Guy G, Walker L, Nathan P, Exley R, Clemens M. Gordon J, et al. Med Oncol Tumor Pharmacother. 1986;3(3-4):269-73. doi: 10.1007/BF02935004. Med Oncol Tumor Pharmacother. 1986. PMID: 3027466 Review.
Cited by
- Human granzyme B regulatory B cells prevent effector CD4+CD25- T cell proliferation through a mechanism dependent from lymphotoxin alpha.
Sailliet N, Mai HL, Dupuy A, Tilly G, Fourgeux C, Braud M, Giral M, Robert JM, Degauque N, Danger R, Poschmann J, Brouard S. Sailliet N, et al. Front Immunol. 2023 Jul 31;14:1183714. doi: 10.3389/fimmu.2023.1183714. eCollection 2023. Front Immunol. 2023. PMID: 37588598 Free PMC article. - A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma.
Wang FH, Wang Y, Chen ZD, Chen JH, Qin FZ, Jiang WQ, Li YH. Wang FH, et al. Med Oncol. 2016 Nov;33(11):125. doi: 10.1007/s12032-016-0846-5. Epub 2016 Oct 14. Med Oncol. 2016. PMID: 27743200 Clinical Trial. - The role of chalcones in suppression of NF-κB-mediated inflammation and cancer.
Yadav VR, Prasad S, Sung B, Aggarwal BB. Yadav VR, et al. Int Immunopharmacol. 2011 Mar;11(3):295-309. doi: 10.1016/j.intimp.2010.12.006. Epub 2010 Dec 22. Int Immunopharmacol. 2011. PMID: 21184860 Free PMC article. Review. - Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells.
Spadavecchia S, Gonzalez-Lopez O, Carroll KD, Palmeri D, Lukac DM. Spadavecchia S, et al. J Virol. 2010 Oct;84(20):10488-500. doi: 10.1128/JVI.00894-10. Epub 2010 Aug 4. J Virol. 2010. PMID: 20686042 Free PMC article. - CKII site in Epstein-Barr virus nuclear protein 2 controls binding to hSNF5/Ini1 and is important for growth transformation.
Kwiatkowski B, Chen SY, Schubach WH. Kwiatkowski B, et al. J Virol. 2004 Jun;78(11):6067-72. doi: 10.1128/JVI.78.11.6067-6072.2004. J Virol. 2004. PMID: 15141006 Free PMC article.
References
- J Virol. 1990 Jun;64(6):3033-41 - PubMed
- Blood. 1992 Apr 1;79(7):1763-7 - PubMed
- Blood. 1992 Apr 1;79(7):1789-95 - PubMed
- Immunol Today. 1992 May;13(5):151-3 - PubMed
- J Natl Cancer Inst. 1961 Aug;27:471-83 - PubMed